Topic: Health

Scientists discovered a protein that makes CAR T-cell therapy less effective. By disabling this protein, called NFIL3, they found that CAR T cells stayed active longer and were better at attacking tumors.

CAR T-cell therapy is a powerful treatment for some blood cancers. However, it has not been very successful against solid tumors. Researchers from Columbia University and University Hospital Tübingen wanted to understand why. They analyzed over 400 proteins that control gene expression in cells and found that NFIL3 was a major contributor to CAR T-cell exhaustion. This means that the cells gradually lose their ability to function effectively.

When they removed NFIL3, the CAR T cells stayed active for longer periods, multiplied more efficiently, and maintained stronger anti-tumor effects. The team used CRISPR/Cas9 gene-editing technology to disable the gene responsible for producing NFIL3.

The benefits of removing NFIL3 were demonstrated across several mouse models. CAR T cells lacking the protein were more effective at controlling tumors and helped extend survival. This suggests a possible path toward improving treatment for cancers that currently respond poorly to CAR T-cell therapy, particularly solid tumors.

Why It Matters

This breakthrough could lead to better treatment options for Indian patients with cancer. It's especially important because many types of cancer are more common in India than in Western countries.

Key Facts

• CAR T-cell therapy is a type of personalized cancer treatment that involves collecting a patient's own immune cells, genetically modifying them, and then returning them to the body.
• NFIL3 was found to be a major contributor to CAR T-cell exhaustion, which means that the cells gradually lose their ability to function effectively.
• Removing NFIL3 led to CAR T cells staying active for longer periods, multiplying more efficiently, and maintaining stronger anti-tumor effects.

Key Terms

NFIL3

A protein that makes CAR T-cell therapy less effective

Implications

This breakthrough could lead to better treatment options for Indian patients with cancer. It's especially important because many types of cancer are more common in India than in Western countries.